[Brentuximab vedotin for Hodgkin´s lymphoma]
Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Urtasun M, Soto N
Record ID 32014000249
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and coverage policy related issues on the use of brentuximab vedotin in patients with Hodgkin´s lymphoma.
Authors' recommendations:
The quality of the available evidence to date is very poor and is based on case series reporting interim result measurements and short term follow-up. However, the efficacy data and toxicity profile suggest brentuximab vedotin might be a therapeutic alternative for resistant or relapsing HL patients failing in at least two lines of treatment and in whom HDT/ASCR is contraindicated, or if HDT/ASCR fails.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.iecs.org.ar/home-ets/?cod_publicacion=1554&familia=5&origen_publicacion=buscador
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Hodgkin Disease
- Brentuximab Vedotin
- Antineoplastic Agents, Immunological
- Antibodies, Monoclonal, Humanized
- Immunotoxins
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.